Phio PharmaceuticalsPHIO
13F holders, Q3 2024 (September 30)6holders
$3.45avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings. The largest holders were Sabby Management, LLC ($87K), UBS Group AG ($6K) and Tower Research Capital LLC (TRC) ($4K).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $98K |
| Exits | 0 | $0 |
Ownership 6 holders
| Sabby Management, LLC | 1.21% | New | 25,131 | $87K |
| UBS Group AG | 0.00% | New | 1,685 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,174 | $4K |
| Nordwand Advisors, LLC | 0.00% | New | 500 | $2K |
| Activest Wealth Management | 0.00% | New | 9 | $31 |
| Bank of America Corp. | 0.00% | New | 7 | $24 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.